Parametric Portfolio Associates LLC decreased its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 27.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 37,072 shares of the medical research company’s stock after selling 14,262 shares during the period. Parametric Portfolio Associates LLC owned 0.08% of Enzo Biochem worth $310,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ENZ. Kempner Capital Management Inc. boosted its stake in shares of Enzo Biochem by 36.4% in the first quarter. Kempner Capital Management Inc. now owns 95,476 shares of the medical research company’s stock worth $799,000 after buying an additional 25,475 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Enzo Biochem by 25.5% in the first quarter. Nationwide Fund Advisors now owns 110,019 shares of the medical research company’s stock worth $921,000 after buying an additional 22,331 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Enzo Biochem by 60.7% in the fourth quarter. Teachers Advisors LLC now owns 112,023 shares of the medical research company’s stock worth $777,000 after buying an additional 42,302 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Enzo Biochem by 16.9% in the first quarter. Russell Investments Group Ltd. now owns 180,973 shares of the medical research company’s stock worth $1,515,000 after buying an additional 26,191 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Enzo Biochem by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock worth $1,728,000 after buying an additional 2,409 shares in the last quarter. Institutional investors and hedge funds own 61.27% of the company’s stock.

Shares of Enzo Biochem, Inc. (NYSE:ENZ) opened at 11.42 on Friday. The firm’s 50 day moving average is $11.16 and its 200-day moving average is $8.74. The firm has a market capitalization of $529.97 million, a PE ratio of 16.02 and a beta of 0.97. Enzo Biochem, Inc. has a 12 month low of $4.88 and a 12 month high of $12.04.

COPYRIGHT VIOLATION NOTICE: “Enzo Biochem, Inc. (ENZ) Position Lowered by Parametric Portfolio Associates LLC” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/05/enzo-biochem-inc-enz-position-lowered-by-parametric-portfolio-associates-llc.html.

A number of equities research analysts have weighed in on the stock. BidaskClub cut shares of Enzo Biochem from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Tuesday, June 20th.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.